Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Chinese Patients With Neovascular Age-Related Macular Degeneration

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
To compare brolucizumab to aflibercept in Chinese patients with untreated active choroidal neovascularization (CNV) secondary to age‐related macular degeneration (AMD)
Epistemonikos ID: a33efb7de76586c1814fcf891aed8dff412be67c
First added on: May 22, 2024